Claritev (NYSE:CTEV - Get Free Report) CEO Travis Dalton bought 1,950 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were bought at an average price of $38.48 per share, for a total transaction of $75,036.00. Following the completion of the acquisition, the chief executive officer owned 52,322 shares in the company, valued at approximately $2,013,350.56. This trade represents a 3.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Travis Dalton also recently made the following trade(s):
- On Thursday, August 27th, Travis Dalton purchased 4,500 shares of Claritev stock. The shares were bought at an average cost of $38.81 per share, for a total transaction of $174,645.00.
Claritev Stock Up 0.6%
NYSE CTEV opened at $39.63 on Tuesday. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07. The business has a 50 day moving average price of $31.43 and a two-hundred day moving average price of $24.87. The stock has a market cap of $671.73 million, a PE ratio of -2.33 and a beta of 0.74.
Claritev (NYSE:CTEV - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.10) by $5.51. The firm had revenue of $257.48 million for the quarter. Sell-side analysts anticipate that Claritev will post -15.13 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have weighed in on CTEV. Weiss Ratings reissued a "sell (d-)" rating on shares of Claritev in a research report on Wednesday, June 24th. Wall Street Zen raised Claritev from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Canaccord Genuity Group boosted their price target on Claritev from $37.00 to $43.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. Citigroup reissued a "buy" rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a report on Monday, August 10th. Finally, Piper Sandler restated an "overweight" rating and set a $73.00 price objective on shares of Claritev in a research note on Wednesday, August 12th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.83.
Get Our Latest Stock Analysis on CTEV
Institutional Investors Weigh In On Claritev
Institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System raised its position in shares of Claritev by 798.0% during the 2nd quarter. California State Teachers Retirement System now owns 4,400 shares of the company's stock valued at $150,000 after acquiring an additional 3,910 shares in the last quarter. Public Investment Fund acquired a new position in Claritev in the second quarter worth $43,703,438. FAS Wealth Partners Inc. increased its stake in Claritev by 49.5% during the first quarter. FAS Wealth Partners Inc. now owns 46,477 shares of the company's stock valued at $759,000 after purchasing an additional 15,380 shares during the last quarter. Bank of America Corp DE increased its stake in Claritev by 146.6% during the first quarter. Bank of America Corp DE now owns 97,795 shares of the company's stock valued at $1,598,000 after purchasing an additional 58,133 shares during the last quarter. Finally, RBF Capital LLC raised its holdings in shares of Claritev by 0.8% during the first quarter. RBF Capital LLC now owns 135,314 shares of the company's stock worth $2,211,000 after purchasing an additional 1,127 shares during the period. 87.15% of the stock is currently owned by institutional investors.
Claritev Company Profile
(
Get Free Report)
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
